Table 4.

Associations between statin use and risk of estrogen receptor (ER) positive or negative breast cancer

	Controls (n = 877)		ER+ ductal cases (n = 727)				ER-ductal cases (n = 149)				ER+ lobular cases (n = 980)
	No.	%	No.	%	OR	95% CI	No.	%	OR	95% CI	No.	%	OR	95% CI
Never use	674	77%	541	74%	1.00	reference	114	77%	1.00	reference	741	76%	1.00	reference
Current use	170	19%	152	21%	1.17	0.90 - 1.51	27	18%	1.00	0.63 - 1.60	208	21%	1.24	0.98 - 1.57
6mo - <5yrs	91	10%	62	9%	0.86	0.60 - 1.22	13	9%	0.86	0.46 - 1.61	104	11%	1.12	0.82 - 1.53
5yrs - <10yrs	47	5%	45	6%	1.28	0.83 - 1.98	8	5%	1.08	0.49 - 2.37	45	5%	0.99	0.64 - 1.53
≥ 10 yrs	31	4%	44	6%	1.97	1.21 - 3.20	6	4%	1.33	0.53 - 3.31	58	6%	2.00	1.26 - 3.17
p-value for trend					p = 0.035				p = 0.740				p = 0.023

OR: odds ratio adjusted for reference year, reference age, county of residence, and hormone therapy use